Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat’AIDS Cohort

Clicks: 12
ID: 332387
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #581 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Long-acting cabotegravir plus rilpivirine (CAB + RPV LA) is highly effective as maintenance therapy in virologically suppressed people with HIV (PWH), but virologic failure (VF) may lead to resistance and compromise future antiretroviral options. Methods We conducted a multicenter observational study within the French Dat'AIDS cohort, including HIV-1 virologically suppressed adults who switched to CAB + RPV LA between December 2021 and December 2023. VF was defined as two consecutive HIV-1 RNA >50 copies/mL or one >200 copies/mL. Remaining options were interpreted using ANRS and Stanford algorithms. Cox models identified factors associated with VF. Results Among 2,196 participants followed for a median of 13 months, VF occurred in 42 individuals (1.9%) after a median of 103 days. Among 26 VF cases undergoing genotype, resistance emerged in 13 (50%), with susceptibility maintained more often for doravirine (ANRS 92%, Stanford 96%) than for dolutegravir/bictegravir (ANRS 58%, Stanford 65%). Resistance also emerged during low-level viremia or transient rebound with re-suppression (7/13 cases). In multivariable analysis, higher BMI (aHR 1.07; 95%CI 1.01-1.14), nadir CD4 < 200 cells/mm3 (aHR 2.44; 1.31-4.56), and prior suppression <12 months (aHR 2.39; 1.01-5.19) were independently associated with VF. Historical CAB and RPV RAMs also increased VF risk. Conclusions CAB + RPV LA was associated with low incidence of VF and rare resistance emergence. When resistance occurred, it primarily compromised bictegravir/dolutegravir rather than doravirine. Low nadir CD4, shorter prior suppression, higher BMI, and historical CAB and/or RPV RAMs support individualized candidate selection and early resistance testing, even during low-level viremia.
Reference Key
openalex_W7221800817 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Colin Deschanvres, Laurent Hocqueloux, André Cabie, Céline Robert, Alain Makinson, Benjamin Lefèvre, David Chirio, Simon Sunder, Cécile Goujard, François Raffi, Véronique Joly, Clotilde Allavena, Dat'AIDS Study Group, C Chirouze, K Bouiller, Fabienne Bozon, A-S Brunel, L Hustache-Mathieu-Hustache, J Lagoutte, Q Lepiller, S Marty-Quinternet, Line Pépin‐Puget, Beatriz Bussi Rosolen, Nadine Tissot, C Lebreton, L Bohard, Sylvain Jaffuel, S Ansart, Y Quintric, S Rezig, Luc Quaesaet, P Gazeau, C Goujard, A Castro-Gordon, P David-Chevallier, V Godard, Yann Quertainmont, Elina Teicher, S Jaureguiberry, L Escaut, M Cresta, B Henry, E Oliosi, C Couzigou, O Derradji, R Collarino, Y Liotier, M Merad, E Zamparini, J Bottero, C Charpentier, D Descamps, Marc Digumber, A. Gervais, J Ghosn, Zélie Julia, R Landman, S Lariven, S Le Gac, Françoise Louni, N Peiffer-Smadja, G Peytavin, Christian Rioux, Yazdan Yazdanpanah, L Deconinck, C Jacomet, N Mrozek, C Theis, M Vidal, C Richaud, V. Corbin, A Benelhadj, A Zaghdoudi, C Aumeran, O Baud, M Berthommier, M Charles, C Durand, D Coban, A Mirand, Alain Brebion, H Chabrolles, O Perruche, E Creuzet, C Henquell, Isabelle Lamaury, G Baronnet, F Bissuel, F Boulard, A Chéret, J Coussement, E Curlier, T Dequidt, C Desfontaines, S Devatine, E Duvallon, I Fabre, Cécile Herrmann‐Storck, C Loraux
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag654
URL
https://doi.org/10.1093/cid/ciag654
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.